Home » Stocks » PODD

Insulet Corporation (PODD)

Stock Price: $297.00 USD 2.12 (0.72%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 19.67B
Revenue (ttm) 904.40M
Net Income (ttm) 6.80M
Shares Out 64.74M
EPS (ttm) 0.10
PE Ratio 2,970.00
Forward PE 312.50
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $297.00
Previous Close $294.88
Change ($) 2.12
Change (%) 0.72%
Day's Open 296.51
Day's Range 292.21 - 298.06
Day's Volume 314,068
52-Week Range 164.40 - 298.43

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ACTON, Mass.--(BUSINESS WIRE)--Q1'21 Earnings Release Schedule

1 week ago - Business Wire

Insulet (PODD) reported earnings 30 days ago. What's next for the stock?

3 weeks ago - Zacks Investment Research

Insulet's (PODD) Omnipod 5 pivotal study showed improvement in glucose control, verified by notable reduction in HbA1c and enhanced time in range together with the lowest rates of hypoglycemia.

3 weeks ago - Zacks Investment Research

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced pos...

4 weeks ago - Business Wire

Here are a few diabetes-centric MedTech stocks, ABT, NVO, MDT, PODD and TNDM, which investors can focus on to reap profits in the new normal.

Other stocks mentioned: ABT, MDT, NVO, TNDM
4 weeks ago - Zacks Investment Research

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced tha...

1 month ago - Business Wire

Insulet's (PODD) Q4 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.

1 month ago - Zacks Investment Research

Shares of Insulet (NASDAQ:PODD) moved lower in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 425.00% year over year to ($0.26), which missed ...

1 month ago - Benzinga

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod Sys...

1 month ago - Business Wire

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that manag...

2 months ago - Business Wire

These are the healthcare stocks with the best value, fastest growth, and most momentum for February 2021.

Other stocks mentioned: BIIB, BIO, CVS, HZNP, MRNA, QDEL, TDOC
2 months ago - Investopedia

Insulet's (PODD) Omnipod DASH system provides 72 hours of continuous insulin therapy, simplifying lives with no more daily injection.

2 months ago - Zacks Investment Research

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod Sys...

3 months ago - Business Wire

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to r...

3 months ago - Business Wire

These are the stocks with the best value, fastest growth, and most momentum for January.

Other stocks mentioned: AGCO, BDN, BPYU, ENPH, FSLY, HDS, MRNA ...
3 months ago - Investopedia

These are the healthcare stocks with the best value, fastest growth, and most momentum for January 2021.

Other stocks mentioned: BIIB, BIO, CVS, HZNP, MRNA, QDEL, XLRN ...
3 months ago - Investopedia

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that manag...

3 months ago - Business Wire

Insulet (PODD) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

These are the healthcare stocks with the best value, fastest growth, and most momentum for December 2020.

Other stocks mentioned: BIO, XLV, MRNA
4 months ago - Investopedia

Medical stocks could be making a comeback this year. The best-performing among them include medical technology companies with high Composite Ratings, a key metric measuring growth.

Other stocks mentioned: ALGN, QDEL, RGEN, RMD
5 months ago - Investors Business Daily

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that manag...

5 months ago - Business Wire

Insulet's (PODD) Q3 gross margin improvement can be primarily attributed to performance of the company's U.S. manufacturing and favorable revenue mix from the shift to higher volume

5 months ago - Zacks Investment Research

Insulet's (PODD) CEO Shacey Petrovic on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Insulet (PODD) delivered earnings and revenue surprises of 183.33% and 5.81%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod Sys...

5 months ago - Business Wire

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod Sys...

5 months ago - Business Wire

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod Sys...

5 months ago - Business Wire

Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities ...

5 months ago - Insider Monkey

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod Sys...

5 months ago - Business Wire

This year, the technology sector is leading the V-shaped recovery from the unprecedented health-hazard-led economic devastation.

Other stocks mentioned: CPRT, ENTG, INTU, ZM
6 months ago - Zacks Investment Research

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today annou...

6 months ago - Business Wire

Insulet (PODD) is optimistic about maintaining growth momentum of its Omnipod system along with tapping the booming diabetes market.

6 months ago - Zacks Investment Research

These are the healthcare stocks with the best value, fastest growth, and most momentum for October 2020.

Other stocks mentioned: BIIB, BIO, CVS, IMMU, LVGO, MRNA, PRGO ...
6 months ago - Investopedia

Here are a few diabetes-centric MedTech stocks that investors can focus on to reap profits amid the pandemic-battered stock market situation.

Other stocks mentioned: ABT, DXCM, MDT
6 months ago - Zacks Investment Research

Insulet (PODD) adds significant capacity in preparation of the Omnipod 5 launch in 2021.

6 months ago - Zacks Investment Research

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod Sys...

6 months ago - Business Wire

Insulet (PODD) reported earnings 30 days ago. What's next for the stock?

7 months ago - Zacks Investment Research

A Relative Strength Rating upgrade for Insulet shows improving technical performance. The post Insulet Shows Market Leadership With Jump To 82 RS Rating appeared first on Investor's Business Daily.

7 months ago - Investors Business Daily

The Dow Jones is looking to finish with 2020 gains at this point, the last of the major 3 indexes to reclaim the title. For those thinking that valuations have run too hot.

Other stocks mentioned: CHWY, FUN, NAV, NYMT
7 months ago - Forbes

Insulet (PODD) adds significant capacity in preparation for the Omnipod 5 launch in 2021.

7 months ago - Zacks Investment Research

Insulet's (PODD) total Omnipod product line comes up with record revenue growth.

8 months ago - Zacks Investment Research

Insulet's (PODD) CEO Shacey Petrovic on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Insulet (PODD) delivered earnings and revenue surprises of 2300.00% and 6.79%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod Sys...

8 months ago - Business Wire

Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

Insulet sees its Relative Strength Rating hit the 80-plus level. The post Insulet Shows Market Leadership With Jump To 81 RS Rating appeared first on Investor's Business Daily.

8 months ago - Investors Business Daily

Insulet: A Good Time To Pick Up A Promising Stock

9 months ago - Seeking Alpha

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today ann...

9 months ago - Business Wire

As the prevalence of diabetes has grown, these companies are looking for solutions.

Other stocks mentioned: DXCM, LVGO
9 months ago - The Motley Fool

About PODD

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is... [Read more...]

Industry
Medical Devices
IPO Date
May 15, 2007
CEO
Shacey Petrovic
Employees
1,900
Stock Exchange
NASDAQ
Ticker Symbol
PODD
Full Company Profile

Financial Performance

In 2020, Insulet's revenue was $904.40 million, an increase of 22.51% compared to the previous year's $738.20 million. Earnings were $6.80 million, a decrease of -41.38%.

Financial Statements

Analyst Forecasts

According to 21 analysts, the average rating for Insulet stock is "Buy." The 12-month stock price forecast is 287.19, which is a decrease of -3.30% from the latest price.

Price Target
$287.19
(-3.30% downside)
Analyst Consensus: Buy